NittoPhase® HL Loaded up to 400umol/g delivers Market Leading Economies to Reduce Synthesis Costs and Increase Yields
Oceanside, CA (PRWEB) April 26, 2010 -- Kinovate Life Sciences, Inc., a California based subsidiary of Nitto Denko Corporation, and the market leader in solid support for oligonucleotide synthesis, will be launching its next generation high loading polymeric solid support product NittoPhase®HL for oligonucleotide synthesis at the TIDES meeting commencing in Boston on April 26th. In thorough testing, NittoPhase®HL loaded at 350umol/g and 250umol/g has shown consistently strong yields and excellent full length purity when utilized for DNA and RNA synthesis respectively. The product will also be commercialized loaded both with succinate and Universal Linker at various levels up to 400umol/g for various applications. Custom loadings included various modified linkers and loading levels will also be available. Kinovate will still continue to sell its market leading original NittoPhase® product.
Utilizing the unparalleled polymer synthesis and R&D capabilities of Nitto Denko Corporation, and the worldwide marketing operations of Kinovate Life Sciences, this new product promises to deliver significantly improved technical and economic outcomes for all segments of the oligonucleotide industry.
Solid support is the base structure used in the synthesis of oligonucleotides, including diagnostic probes and primers, antisense including RNAi, microRNA, DNA-based and aptamer drugs and represents a substantial portion of the cost to manufacture these oligonucleotides. The market leading loading capacity of NittoPhase®HL results in significantly improved yields per gram of material with superior purity, allowing users to realize significant cost savings with no compromise in quality.
“NittoPhase®HL truly represents a quantum leap in soli
Copyright©2010 Vocus, Inc.
All rights reserved